Cancer immunotherapy

Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022

Retrieved on: 
Wednesday, April 27, 2022
IC50, Monocyte, COVID-19, Research, GLOBE, Patient, Ivermectin, Technology, Breast cancer, Immune system, OTCQB, TBIA, Synthase, Cell cycle, Knowledge, Alzheimer's disease, Pressure, U.S. Securities and Exchange Commission, Cancer immunotherapy, Company, Observational study, Solution, TMB-2, Disease, Overalls, CEO, MERS, Legislation, Good, Dietary supplement, Plasma, Apoptosis, Coronavirus, Neurodegeneration, GCP, IRB, Biotechnology, Neuron, Brain, PCR, Institutional review board, Method, Â, Physician, Cancer, COVID, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Medical imaging, Long COVID

Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID.

Key Points: 
  • Tollovid and Tollovid Daily are not approved to diagnose, treat, prevent or cure any disease, including COVID and/or Long COVID.
  • Concurrent with this announcement, the Company announced that it will be offering a 50% discount on the price of Tollovid Maximum Strength through close of business on May 31st, 2022.
  • In the last year we have heard anecdotal reports from customers who have experienced great success using our dietary supplements, said Gerald E. Commissiong, President and CEO of Todos Medical.
  • Based on these, we are preparing for an observational study for Tollovid in Long COVID, and have received overwhelming interest from physicians and patients in participating.

Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group

Retrieved on: 
Tuesday, April 19, 2022
IC50, Monocyte, COVID-19, Research, Ministry of Culture, Information, Sports and Youth Policy (Kyrgyzstan), GLOBE, Sale, Patient, Technology, Immune system, OTCQB, TBIA, Synthase, Cell cycle, Knowledge, Alzheimer's disease, Pressure, Athlete, U.S. Securities and Exchange Commission, ISO, Cancer immunotherapy, Company, Solution, CGMP, TMB-2, Certification, Sport, CEO, MERS, Legislation, Plasma, Apoptosis, Laboratory, Coronavirus, Neurodegeneration, Accreditation, Biotechnology, Neuron, Brain, PCR, Method, Cancer, Risk, COVID, Lymphocyte, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Dietary supplement, Medical imaging, Amazon

Informed Sport is a global testing and certification program for sports and nutritional supplements.

Key Points: 
  • Informed Sport is a global testing and certification program for sports and nutritional supplements.
  • Supplement products are tested by LGC Group s world-class anti-doping laboratory for contamination against a broad range of banned substances in sport, using ISO 17025 accredited methods.
  • Established in 2008, Informed Sport has certified over 3,000 unique products sold in over 127 countries globally.
  • Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support.

ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Olive, EMSO, Therapy, Acute myeloid leukemia, Degenerative disease, Malignancy, Prostate, Research, Head, Mab, Poster, Neoplasm, MD, Association, American Association for Cancer Research, HNSCC, Hematological Cancer Research Investment and Education Act, Immunology, CD8, Pancreatic cancer, SITC, Pembrolizumab, Breast, CDT, American Association, Follicular lymphoma, CNRS, Large-cell lung carcinoma, Cancer immunotherapy, Cancer, Lung, CPI, Clinical trial, AACR, Part, Doctor of Philosophy, CD3, Ovarian cancer, Melanoma, Acute leukemia, NK, Patient, Antibody, Ovary, Tumor microenvironment, Group C, INSERM, Safety, Group B, T, Infection, Pharmaceutical industry, Vaccine, Butyrophilin, subfamily 1, member A1

Marseille, France, April 8, 2022 ImCheck Therapeutics provided newly updated patient response data from its ongoing EVICTION Phase I/IIa clinical trial of its lead candidate ICT01 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • Marseille, France, April 8, 2022 ImCheck Therapeutics provided newly updated patient response data from its ongoing EVICTION Phase I/IIa clinical trial of its lead candidate ICT01 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022.
  • In efficacy evaluable patients (n=22) treated with the combination of low dose ICT01 plus pembrolizumab who previously failed at least one prior checkpoint inhibitor (CPI) regimen, 36% showed disease control by RECIST1.1 criteria.
  • Part 2 of the trial is a Phase II cohort expansion study in selected indications as both monotherapy and in combination.
  • ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.

Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Retrieved on: 
Tuesday, March 29, 2022
Spindle, Treatment, Form 10-K, VVIP, RATS, Tumor microenvironment, Therapy, PALO, Complex conjugate, Patent, Forward-looking statement, Optimus, Clinical trial, Patient, GLP, New Frontier, Research, Failure, Chronic lymphocytic leukemia, Neoplasm, Tissue, SMDC, G&A, Safety, Control, Cancer immunotherapy, NIH, Securities Exchange Act of 1934, Lists of Transformers characters, Securities Act of 1933, Conjugation, Nasdaq, COVID-19, Dog, GLOBE, 8-K, Prednisone, Acceleration, Drug Quality and Security Act, Lymphatic system, R, Accounting, Drug design, Insurance, Pembrolizumab, Toxicity, Pharmaceutical industry, Vaccine, Fine chemical, Risk management, Cancer, IND, Bayer

We remain on track to initiate Phase 2 studies of VIP152 in the second half of this year.

Key Points: 
  • We remain on track to initiate Phase 2 studies of VIP152 in the second half of this year.
  • We are on-target to file an IND for VIP236 in the second half of the year, continued Dr. Hamdy.
  • For the fourth quarter and full year 2021, Vincerx reported a net loss of $6.5 million, or $0.31 per share, and a net loss of $39.3 million, or $2.29 per share, respectively.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.

Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products

Retrieved on: 
Monday, March 28, 2022
Method, Plasma, Research, Health, Biotechnology, Neurodegeneration, CEO, Technology, Knowledge, GLOBE, Solution, TBIA, Disease, Sale, TMB-2, Certification, Apoptosis, Immune system, Mechanic, U.S. Securities and Exchange Commission, Brain, Neuron, Hospital, Cancer, Cell cycle, IC50, Synthase, Lymphocyte, Death, Coronavirus, MERS, Legislation, Karate, Severe acute respiratory syndrome coronavirus 2, Man, Pfizer, OTCQB, Athlete, COVID, Awareness, FDA, Instagram, Social media, Monocyte, Patient, Cancer immunotherapy, PCR, Plant, Woman, Pressure, COVID-19, Facebook, Nature, Alzheimer's disease, Pharmaceutical industry, Medical imaging, Company

As the first Tollovid brand ambassador, Mr. Blanks has been asked to help create content for the Tollovid brand so that it can be spread over key social media platforms.

Key Points: 
  • As the first Tollovid brand ambassador, Mr. Blanks has been asked to help create content for the Tollovid brand so that it can be spread over key social media platforms.
  • Tollovid was first introduced to me at the Celebrity Flag Football Challenge during the 2022 Super Bowl Weekend, said Billy Blanks.
  • I follow the recommended use of Tollovid noted on the bottle, however, always consult your own doctor if you have questions.
  • Billy and I had a great conversation about Tollovid at the Celebrity Flag Football Challenge, said Gerald Commissiong, CEO of Todos Medical.

Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma

Retrieved on: 
Wednesday, March 16, 2022
Time, Solution, Technology, Dietary supplement, OTCQB, Standard of care, PCR, TBIA, CEO, U.S. Securities and Exchange Commission, TMB-2, NLC, Intellectual property, Legislation, Acquisition, Apoptosis, School, Plasma, MERS, Synthase, COVID-19, Hospital, COVID, Infection, Airport, Lymphocyte, Research, Cancer immunotherapy, Immune system, Pharma, Pressure, Method, Patient, Monocyte, Therapy, Brain, NEW, Alzheimer's disease, Cancer, Coronavirus, Disease, Doctor of Philosophy, GLOBE, NCE, Knowledge, Pediatrics, Quarantine, Company, Cell cycle, Neuron, Industry, Biotechnology, Biology, Neurodegeneration, Pharmaceutical industry, Medical device, Vaccine, Rotavirus, Severe acute respiratory syndrome coronavirus 2

NEW YORK, NY and Tel Aviv, ISRAEL, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has completed the acquisition of all 3CL protease biology-related assets and formed a majority-owned subsidiary called 3CL Pharma Ltd. (“3CL Pharma”). 3CL Pharma will focus on developing therapeutics, diagnostics and dietary supplements based on 3CL protease (3CLpro, Main Protease, Mpro, Nsp5) biology related work of Dr. Dorit Arad, who joins Todos Medical as the newly appointed Chief Scientific Officer. This acquisition solidifies Todos Medical’s position as a key player in the development and commercialization of 3CL protease-related products. These assets currently include:

Key Points: 
  • This acquisition solidifies Todos Medicals position as a key player in the development and commercialization of 3CL protease-related products.
  • Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates.
  • The data we announced in the third quarter of 2021 showed PCR-like sensitivity one to three days after infection.
  • This marks a major milestone for Todos and the next steps in our Companys long-term growth plans.

Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia as Chief Executive Officer

Retrieved on: 
Wednesday, March 9, 2022
Nasdaq, Life Technologies, Industry, Telecommunication, Company, Therapy, CFO, Cell, Culture, Antibody, U.S. Securities and Exchange Commission, Laboratory, FOR, RESEARCH, Electronics, Board, Scripps Research, McKinsey & Company, Johns Hopkins University, Leadership, Risk, GLOBE, Cancer immunotherapy, B.E, Biomedical engineering, Eurofins Scientific, Biology, Wood, Growth, Doctor of Philosophy, Rutgers University, Gujarat University, CEO, Management, Risk management

EMERYVILLE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) (Berkeley Lights or the Company) a leader in digital cell biology, today announced it has appointed Dr. Siddhartha Kadia as its new chief executive officer (CEO), effective immediately.

Key Points: 
  • EMERYVILLE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) (Berkeley Lights or the Company) a leader in digital cell biology, today announced it has appointed Dr. Siddhartha Kadia as its new chief executive officer (CEO), effective immediately.
  • Dr. Kadia will remain a member of the Berkeley Lights Board of Directors.
  • Siddhartha is an experienced life science executive exceptionally well positioned to lead our company and enhance shareholder value, said Gregory T. Lucier, chairperson of Berkeley Lights Board of Directors.
  • Having joined Berkeley Lights Board last year, Siddhartha is ready to hit the ground running and we expect a seamless transition.

Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, March 9, 2022
Lung, Risk, OVS, U.S. Securities and Exchange Commission, Investor, Private Securities Litigation Reform Act, Brain, Society, HSV, PD-1, Therapy, GBM, Program, Safety, Drug, Drug development, Company, Annual general meeting, Orthornavirae, GLOBE, Preventing Sex Trafficking and Strengthening Families Act, Patient, PD-L1, MicroRNA, RNA, Head, Clinical trial, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, LNP, Annual report, Transgene, Cancer, Conference, SITC, Security (finance), Neoplasm, Pembrolizumab, Immunotherapy, Glioblastoma, Insurance, RNA transfection, Nasdaq, Potyvirus, Research, Investment, Mark (given name), GLP, Neck, Society for Immunotherapy of Cancer, COVID-19, Cancer immunotherapy, Cryptocurrency, Pharmaceutical industry, Vaccine, IND

In 2021, Oncorus made meaningful progress advancing our pipeline of next-generation, systemically active viral immunotherapies.

Key Points: 
  • In 2021, Oncorus made meaningful progress advancing our pipeline of next-generation, systemically active viral immunotherapies.
  • The Phase 1 presentation at SITC marked Oncorus first reporting of human data from its HSV platform.
  • Research and development expenses for the quarter ended December 31, 2021 were $14.3 million compared to $7.6 million for the corresponding quarter in 2020.
  • General and administrative expenses for the quarter ended December 31, 2021 were $5.6 million compared to $4.0 million for the corresponding quarter in 2020.

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Retrieved on: 
Thursday, February 17, 2022
Oncology, Health, Other Health, Research, Science, Biotechnology, History, Cancer immunotherapy, Therapeutic index, RNA, Vaccine, Drug Quality and Security Act, Private Securities Litigation Reform Act, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRISPR, DNA, COVID-19, Russell, United States Department of State, Company, SEC, Manuscript, TSA, Securities Act of 1933, Twitter, Survival, Research, USDA, TAA, NASDAQ, Textile, United States Department of Agriculture, Infection, PETS, Cancer, TERT, B-cell lymphoma, LinkedIn, Bharathidasan University, Zoonosis, Lymphoma, Mouse, TAAS, Program, Food, CEO, Forward-looking statement, Immunotherapy, Cannabis, PCR, COVID-19 testing, Annual report, Securities Exchange Act of 1934, ICI, FDA, Polymerase chain reaction, Mouse Models of Human Cancer database, TCR, Applied DNA Sciences, Veterinary medicine, Applied DNA Sciences, Evvivax, APPLIED DNA SCIENCES, EVVIVAX

("Evvivax"), today announced the publication of a manuscript detailing a preclinical study (the study) showing that LinearDNA vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models.

Key Points: 
  • ("Evvivax"), today announced the publication of a manuscript detailing a preclinical study (the study) showing that LinearDNA vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models.
  • LinearDNA is Applied DNAs proprietary, large-scale polymerase chain reaction ("PCR")-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
  • The TERT DNAvaccine was designed by EvviVax and exclusively licensed by the Company for the LinearDNA platform for veterinary applications.
  • In the study, LinearDNA and plasmid DNA forms of the personalized cancer vaccine were administered to mice in the colon cancer model.

Berkeley Lights Announces CEO Transition and Preliminary Full Year 2021 Financial Update

Retrieved on: 
Wednesday, January 5, 2022
Therapy, Growth, Director, Company, Russell Reynolds Associates, Cell, U.S. Securities and Exchange Commission, Conference, Life Technologies, Contract, Culture, Risk, RESEARCH, CEO, IPO, Thermo Fisher Scientific, Beacon, Cancer immunotherapy, Partnership, Board, Adoption, GLOBE, Technology, Antibody, Nasdaq, FOR, Leadership, Interest, Management, 3D printing, Lithium

His deep knowledge of this area, including Berkeley Lights technology, customers and future R&D roadmap, will help ensure successful business continuity.

Key Points: 
  • His deep knowledge of this area, including Berkeley Lights technology, customers and future R&D roadmap, will help ensure successful business continuity.
  • Under Erics leadership as CEO, Berkeley Lights has realized a more than a 10-fold revenue increase, released multiple transformational products, and completed a successful IPO in 2020, said Gregory T. Lucier, chairperson of Berkeley Lights board of directors.
  • During 2021, the Company began to enter new markets through a partnership/service-based business model, leveraging the Berkeley Lights Platform through its BioFoundry lab.
  • Revenue from the partnership/service business grew three-fold in 2021 and drove approximately 20% of the Companys overall 2021 revenue.